186 related articles for article (PubMed ID: 24748116)
1. End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability.
Luo Y; Li D; Ran J; Yan B; Chen J; Dong X; Liu Z; Liu R; Zhou J; Liu M
Protein Cell; 2014 Jun; 5(6):469-79. PubMed ID: 24748116
[TBL] [Abstract][Full Text] [Related]
2. +TIP EB1 downregulates paclitaxel‑induced proliferation inhibition and apoptosis in breast cancer cells through inhibition of paclitaxel binding on microtubules.
Thomas GE; Sreeja JS; Gireesh KK; Gupta H; Manna TK
Int J Oncol; 2015 Jan; 46(1):133-46. PubMed ID: 25310526
[TBL] [Abstract][Full Text] [Related]
3. Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity.
Sun X; Li D; Yang Y; Ren Y; Li J; Wang Z; Dong B; Liu M; Zhou J
J Pathol; 2012 Mar; 226(4):666-73. PubMed ID: 21989536
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel.
Zhao W; Song Y; Xu B; Zhan Q
Cancer Biol Ther; 2012 Feb; 13(3):156-63. PubMed ID: 22353935
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
Yang H; Mao W; Rodriguez-Aguayo C; Mangala LS; Bartholomeusz G; Iles LR; Jennings NB; Ahmed AA; Sood AK; Lopez-Berestein G; Lu Z; Bast RC
Clin Cancer Res; 2018 Oct; 24(20):5072-5084. PubMed ID: 30084832
[No Abstract] [Full Text] [Related]
6. Centrosomal Protein 70 Is a Mediator of Paclitaxel Sensitivity.
Shi X; Wang Y; Sun X; Wang C; Jiang P; Zhang Y; Huang Q; Liu X; Li D; Zhou J; Liu M
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28632150
[TBL] [Abstract][Full Text] [Related]
7. Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism.
Wang H; Liu B; Zhang C; Peng G; Liu M; Li D; Gu F; Chen Q; Dong JT; Fu L; Zhou J
J Pathol; 2009 May; 218(1):76-85. PubMed ID: 19214989
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of paclitaxel-induced microtubule stabilization, mitotic arrest, and apoptosis by the microtubule-targeting agent EM012.
Zhou J; Liu M; Aneja R; Chandra R; Joshi HC
Biochem Pharmacol; 2004 Dec; 68(12):2435-41. PubMed ID: 15548390
[TBL] [Abstract][Full Text] [Related]
9. Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest.
Zhao Y; Peng H; Liang L; Li Y; Hu X; Wang B; Xu Y; Chen S
Breast Cancer Res Treat; 2022 Feb; 192(1):75-87. PubMed ID: 35079981
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
11. Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway.
Lai TC; Fang CY; Jan YH; Hsieh HL; Yang YF; Liu CY; Chang PM; Hsiao M
Cell Commun Signal; 2020 Oct; 18(1):164. PubMed ID: 33087151
[TBL] [Abstract][Full Text] [Related]
12. Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.
Amaya C; Luo S; Baigorri J; Baucells R; Smith ER; Xu XX
BMC Cancer; 2021 Sep; 21(1):981. PubMed ID: 34470602
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
Sui M; Huang Y; Park BH; Davidson NE; Fan W
Cancer Res; 2007 Jun; 67(11):5337-44. PubMed ID: 17545614
[TBL] [Abstract][Full Text] [Related]
14. Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo.
Wagner P; Wang B; Clark E; Lee H; Rouzier R; Pusztai L
Cell Cycle; 2005 Sep; 4(9):1149-52. PubMed ID: 16103753
[TBL] [Abstract][Full Text] [Related]
15. High Bak Expression Is Associated with a Favorable Prognosis in Breast Cancer and Sensitizes Breast Cancer Cells to Paclitaxel.
Luo Y; Wang X; Wang H; Xu Y; Wen Q; Fan S; Zhao R; Jiang S; Yang J; Liu Y; Li X; Xiong W; Ma J; Peng S; Zeng Z; Li X; Phillips JB; Li G; Tan M; Zhou M
PLoS One; 2015; 10(9):e0138955. PubMed ID: 26406239
[TBL] [Abstract][Full Text] [Related]
16. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
Wang H; Vo T; Hajar A; Li S; Chen X; Parissenti AM; Brindley DN; Wang Z
BMC Cancer; 2014 Jan; 14():37. PubMed ID: 24447372
[TBL] [Abstract][Full Text] [Related]
17. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells.
Alli E; Yang JM; Ford JM; Hait WN
Mol Pharmacol; 2007 May; 71(5):1233-40. PubMed ID: 17272681
[TBL] [Abstract][Full Text] [Related]
18. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M
Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
Promkan M; Liu G; Patmasiriwat P; Chakrabarty S
Int J Cancer; 2009 Dec; 125(12):2820-8. PubMed ID: 19551867
[TBL] [Abstract][Full Text] [Related]
20. Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy.
Rodrigues-Ferreira S; Nehlig A; Moindjie H; Monchecourt C; Seiler C; Marangoni E; Chateau-Joubert S; Dujaric ME; Servant N; Asselain B; de Cremoux P; Lacroix-Triki M; Arnedos M; Pierga JY; André F; Nahmias C
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23691-23697. PubMed ID: 31685623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
